LPL Financial LLC Decreases Stake in Exelixis (EXEL)

LPL Financial LLC cut its holdings in Exelixis (NASDAQ:EXEL) by 11.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 13,583 shares of the biotechnology company’s stock after selling 1,743 shares during the period. LPL Financial LLC’s holdings in Exelixis were worth $413,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also bought and sold shares of EXEL. American Century Companies Inc. boosted its holdings in shares of Exelixis by 426.4% in the 4th quarter. American Century Companies Inc. now owns 1,469,945 shares of the biotechnology company’s stock valued at $44,686,000 after buying an additional 1,190,691 shares during the period. Jennison Associates LLC lifted its position in Exelixis by 38.1% in the 4th quarter. Jennison Associates LLC now owns 4,228,761 shares of the biotechnology company’s stock valued at $128,554,000 after purchasing an additional 1,167,758 shares during the last quarter. Smith Asset Management Group LP bought a new stake in Exelixis in the 4th quarter valued at about $26,323,000. Caisse DE Depot ET Placement DU Quebec bought a new stake in Exelixis in the 4th quarter valued at about $17,480,000. Finally, Arrowstreet Capital Limited Partnership lifted its position in Exelixis by 34.3% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,843,129 shares of the biotechnology company’s stock valued at $56,031,000 after purchasing an additional 471,023 shares during the last quarter. 80.49% of the stock is owned by institutional investors and hedge funds.

How to Become a New Pot Stock Millionaire

In other news, Director George Poste sold 15,000 shares of Exelixis stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $26.26, for a total value of $393,900.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Patrick J. Haley sold 45,029 shares of Exelixis stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $27.13, for a total transaction of $1,221,636.77. The disclosure for this sale can be found here. Over the last three months, insiders sold 210,029 shares of company stock worth $4,877,737. 5.10% of the stock is currently owned by insiders.

EXEL has been the topic of a number of recent analyst reports. SunTrust Banks restated a “buy” rating and set a $38.00 price target on shares of Exelixis in a research report on Thursday, December 21st. BidaskClub upgraded shares of Exelixis from a “hold” rating to a “buy” rating in a research report on Thursday, January 25th. Cann restated a “buy” rating and set a $40.00 price target on shares of Exelixis in a research report on Thursday, March 8th. William Blair restated a “buy” rating on shares of Exelixis in a research report on Wednesday, April 11th. Finally, TheStreet downgraded shares of Exelixis from a “b” rating to a “c+” rating in a research report on Thursday, March 15th. Two analysts have rated the stock with a sell rating, four have given a hold rating and nine have given a buy rating to the stock. Exelixis presently has an average rating of “Hold” and an average price target of $34.10.

Exelixis stock opened at $21.09 on Friday. The company has a market capitalization of $6,428.60, a PE ratio of 41.35 and a beta of 2.10. Exelixis has a fifty-two week low of $18.03 and a fifty-two week high of $32.50.

Exelixis (NASDAQ:EXEL) last released its earnings results on Monday, February 26th. The biotechnology company reported $0.12 earnings per share for the quarter, hitting the consensus estimate of $0.12. The business had revenue of $120.10 million for the quarter, compared to the consensus estimate of $120.25 million. Exelixis had a net margin of 34.08% and a return on equity of 81.05%. The firm’s quarterly revenue was up 54.8% compared to the same quarter last year. During the same period last year, the firm posted $0.12 earnings per share. research analysts predict that Exelixis will post 0.58 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “LPL Financial LLC Decreases Stake in Exelixis (EXEL)” was first published by Week Herald and is the property of of Week Herald. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://weekherald.com/2018/04/20/lpl-financial-llc-decreases-stake-in-exelixis-exel.html.

Exelixis Company Profile

Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.

Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis (NASDAQ:EXEL).

Institutional Ownership by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply